Bharat Biotech slams criticism of indigenous vaccine Covaxin; we’re a worldwide firm, says CMD
2 min read Image Source : FILE PHOTO/PTI The DCGI has accredited emergency use authorisation to Covaxin, the coronavirus vaccine developed by Bharat Biotech.
Amid questions over emergency approval to Covaxin, Bharat Biotech, the Indian pharma firm which has developed within the COVID-19 vaccine, on Monday described the controversy as uncalled for. Several Opposition events, together with the Congress, have questioned the credibility of Bharat Biotech and the transfer to grant emergency use authorisation to Covaxin.
Speaking throughout a digital press convention, Bharat Biotech MD Krishna Ella sought to clear all doubts over the a lot awaited vaccine in opposition to coronavirus and asserted that he has no political connections.
ALSO READ: ‘Never questioned scientists’: Akhilesh Yadav clarifies his ‘BJP vaccine’ comment
“Now that vaccine is being politicised, I want to state very clearly that none of my family members is associated with any political party,” he mentioned.
“Many people say that I am not transparent in my data. I think people should have patience to read on the internet and how many articles we have published. More than 70 articles have been published in various international journals,” Ella mentioned referring to questions being raised over the info of scientific trials of the vaccine.
COVID-19: World’s largest vaccination programme to start out in India quickly, says PM Modi
“We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh and other countries. We are not just an Indian company, we are truly a global company,” he mentioned.
Underlining that his firm has huge expertise within the discipline, Bharat Biotech MD mentioned that Indian firms are being portrayed in a flawed approach infront of the world.
“We are not a company without experience in vaccines. We have tremendous experience in vaccines. We are touching 123 countries. We are the only company that has got such extensive experience and extensive publication in review journals,” Krishna Ella mentioned.
“Many people are gossiping everything in different directions to just backlash on Indian companies. That is not right for us, we don’t deserve that,” he added.
Latest India News
